ATE296636T1 - Verbesserter heilungsprozess von neuralverletzungen anhand von cm101/gbs-toxin - Google Patents

Verbesserter heilungsprozess von neuralverletzungen anhand von cm101/gbs-toxin

Info

Publication number
ATE296636T1
ATE296636T1 AT98904795T AT98904795T ATE296636T1 AT E296636 T1 ATE296636 T1 AT E296636T1 AT 98904795 T AT98904795 T AT 98904795T AT 98904795 T AT98904795 T AT 98904795T AT E296636 T1 ATE296636 T1 AT E296636T1
Authority
AT
Austria
Prior art keywords
neural
healing process
gbs toxin
improved healing
neural injuries
Prior art date
Application number
AT98904795T
Other languages
English (en)
Inventor
Carl G Hellerqvist
Artur W Wamil
Barbara D Wamil
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE296636T1 publication Critical patent/ATE296636T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98904795T 1997-01-29 1998-01-29 Verbesserter heilungsprozess von neuralverletzungen anhand von cm101/gbs-toxin ATE296636T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/791,857 US5981508A (en) 1997-01-29 1997-01-29 Facilitation of repair of neural injury with CM101/GBS toxin
PCT/US1998/001851 WO1998032448A1 (en) 1997-01-29 1998-01-29 Facilitation of repair of neural injury with cm101/gbs toxin

Publications (1)

Publication Number Publication Date
ATE296636T1 true ATE296636T1 (de) 2005-06-15

Family

ID=25154992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904795T ATE296636T1 (de) 1997-01-29 1998-01-29 Verbesserter heilungsprozess von neuralverletzungen anhand von cm101/gbs-toxin

Country Status (8)

Country Link
US (2) US5981508A (de)
EP (1) EP0981353B1 (de)
JP (1) JP2001511136A (de)
AT (1) ATE296636T1 (de)
AU (1) AU6258798A (de)
DE (1) DE69830400T2 (de)
ES (1) ES2244046T3 (de)
WO (1) WO1998032448A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803448B1 (en) 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
EP2000134A1 (de) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Verwendung einer Substanz zur Behandlung von Verletzungen des peripheren Nervensystems
TW202541819A (zh) * 2023-12-27 2025-11-01 日商安斯泰來製藥股份有限公司 脊髓損傷之治療用醫藥組成物及脊髓損傷之非人類靈長類動物模式之製作方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS557014A (en) * 1978-06-29 1980-01-18 Chugai Pharmaceut Co Ltd Antitumor agent and its preparation
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
US4895838A (en) * 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US5010062A (en) * 1989-09-25 1991-04-23 Vanderbilt University Therapeutic agent and method of inhibiting vascularization of tumors
US5225331A (en) * 1991-04-25 1993-07-06 National Research Council Of Canada Immunoassay for detecting group b streptococcus
US5382514A (en) * 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
EP0666868B2 (de) * 1992-10-28 2006-06-14 Genentech, Inc. Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
CA2212370A1 (en) * 1995-02-16 1996-08-22 Moses Judah Folkman Inhibition of angiogenesis using interleukin-12
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5811403A (en) * 1996-09-30 1998-09-22 Vanderbilt University Polysaccharide toxin from Group B β-hemolytic Streptococcus (GBS) having improved purity
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin

Also Published As

Publication number Publication date
AU6258798A (en) 1998-08-18
EP0981353A1 (de) 2000-03-01
US5981508A (en) 1999-11-09
DE69830400T2 (de) 2006-01-26
ES2244046T3 (es) 2005-12-01
JP2001511136A (ja) 2001-08-07
WO1998032448A1 (en) 1998-07-30
EP0981353B1 (de) 2005-06-01
US6476001B1 (en) 2002-11-05
DE69830400D1 (de) 2005-07-07

Similar Documents

Publication Publication Date Title
EP2174662A3 (de) Verfahren zur Behandlung von Muskelstörungen
ATE302020T1 (de) Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
PT822829E (pt) Utilizacao do factor neurotrofico da glia (gdnf) para o tratamento de desordens da audicao
MY113059A (en) Controlled-release dosage forms of azithromycin
ES2148826T3 (es) Metodo para tratar una lesion ganglionar de la retina usando un producto proteinico de factor neurotrofico obtenido de la linea celular glialica (gdnf).
WO1995017154A3 (en) Use of thalidomide for treating neurocognitive disorders
WO2001093893A3 (en) The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
ES2190093T3 (es) Uso de un producto proteico de neurturina para prevenir y tratar la perddida de audicion.
GEP20033083B (en) Method For Stimulation and Cupping Ventricular Arrhythmia
CA2400801A1 (en) Treatment of congestive heart failure by pretreated autologous blood
EP0933995B8 (de) Verfahren zur behandlung von endothelialen verletzungen
ZA944347B (en) The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
ATE241375T1 (de) Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
ATE296636T1 (de) Verbesserter heilungsprozess von neuralverletzungen anhand von cm101/gbs-toxin
ES2196539T3 (es) Facilitacion de la cicatrizacion con la toxina cm101/gbs.
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
Pearlman et al. ECT-valproic acid interaction.
IL159770A0 (en) Calcium salts with cytotoxic activity
ECSP013869A (es) Tratamiento del dolor
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
RU96115809A (ru) Способ лечения сочетанной челюстно-мозговой травмы
BR9713828A (pt) Tratamento de tumores altamente vasculares
UA33293A (uk) Спосіб лікування травматичних ушкоджень рогової оболонки

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties